$21.74
2.51% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

ACADIA Pharmaceuticals Inc. Stock price

$21.74
+4.22 24.09% 1M
+4.48 25.96% 6M
+3.39 18.47% YTD
+6.37 41.44% 1Y
-24.11 52.58% 5Y
-17.66 44.82% 10Y
+12.84 144.27% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.56 2.51%
ISIN
US0042251084
Symbol
ACAD
Sector
Industry

Key metrics

Market capitalization $3.64b
Enterprise Value $2.96b
P/E (TTM) P/E ratio 15.87
EV/FCF (TTM) EV/FCF 59.75
EV/Sales (TTM) EV/Sales 2.97
P/S ratio (TTM) P/S ratio 3.65
P/B ratio (TTM) P/B ratio 4.75
Revenue growth (TTM) Revenue growth 22.39%
Revenue (TTM) Revenue $995.97m
EBIT (operating result TTM) EBIT $235.00m
Free Cash Flow (TTM) Free Cash Flow $49.48m
Cash position $682.00m
EPS (TTM) EPS $1.37
P/E forward 41.77
P/S forward 3.42
EV/Sales forward 2.78
Short interest 15.68%
Show more

Is ACADIA Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

ACADIA Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

12x Buy
63%
6x Hold
32%
1x Sell
5%

Analyst Opinions

19 Analysts have issued a ACADIA Pharmaceuticals Inc. forecast:

Buy
63%
Hold
32%
Sell
5%

Financial data from ACADIA Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
996 996
22% 22%
100%
- Direct Costs 79 79
25% 25%
8%
917 917
22% 22%
92%
- Selling and Administrative Expenses 506 506
22% 22%
51%
- Research and Development Expense - -
-
-
236 236
3,974% 3,974%
24%
- Depreciation and Amortization 0.91 0.91
91% 91%
0%
EBIT (Operating Income) EBIT 235 235
4,939% 4,939%
24%
Net Profit 229 229
17,715% 17,715%
23%

In millions USD.

Don't miss a Thing! We will send you all news about ACADIA Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACADIA Pharmaceuticals Inc. Stock News

Neutral
Business Wire
4 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for the District of Delaware in December 2023 confirming validity of the NUPLAZID® (pimavanserin) '740 composition of matter patent. The affirmance came in Acadia's litigation against MSN Laboratories ...
Neutral
Business Wire
8 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced it will host a R&D day in New York City to discuss its neurological and rare diseases pipeline on Wednesday, June 25, 2025 at 8:30 AM ET. The event will feature members of Acadia's management team and R&D organization, key opinion leaders (KOL) and members of the caregiver community. To register for the live ...
Neutral
Business Wire
15 days ago
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 4:00 p.m. Eastern Time. A live webcast of Acadia's fireside chat will be accessible on the company's website, Acadia.com, under the investors section and an archived recording w...
More ACADIA Pharmaceuticals Inc. News

Company Profile

ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Head office United States
CEO Catherine Adams
Employees 654
Founded 1993
Website acadia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today